Jean-Jacques Kiladjian/LinkedIn
Oct 12, 2026, 12:12
Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
Jean-Jacques Kiladjian, Head of Clinical Research Department of Inserm, Professor of Medicine at the University of Paris Cité, President of the FIM, shared a post on LinkedIn:
“Ready to give my last lecture at 88 JSH about optimizing treatment strategy for JAK inhibitors in myelofibrosis.
It was also a good opportunity to meet again with Japanese colleagues and friends and discuss possible collaboration.
Thanks in particular to Pr Norio Komatsu, Pr Kazuya Shimoda, Pr Keita Kirito and colleagues for their warm welcome.”
Stay updated with Hemostasis Today.
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026
-
Oct 12, 2026, 10:36PAI-1 Inhibition as a New Strategy for Enhancing Fibrinolysis and Clot Resolution
-
Oct 12, 2026, 07:39Emmanuel J Favaloro: 100 Years of von Willebrand Disease and the Importance of Local Diagnosis and Management
-
Oct 12, 2026, 07:39Post-Stroke Fatigue Trajectories – 38% Recovered at 12 Months, While 16% Developed New Fatigue – International Journal of Stroke
-
Oct 12, 2026, 07:28Beth Sara: IBMS Specialist Portfolio Achievement and a New Role in Transfusion Practice
-
Oct 12, 2026, 07:28Abdul Mannan: PCC vs. aPCC – The Small ‘a’ That Changes Emergency Management